Jennifer MinaiAzary - Context Therapeutics CFO Treasurer
| CNTX Stock | USD 0.91 0.01 1.11% |
Insider
Jennifer MinaiAzary is CFO Treasurer of Context Therapeutics
| Age | 47 |
| Address | 2001 Market Street, Philadelphia, PA, United States, 19103 |
| Phone | 267-225-7416 |
| Web | https://www.contexttherapeutics.com |
Context Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2522) % which means that it has lost $0.2522 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3725) %, meaning that it created substantial loss on money invested by shareholders. Context Therapeutics' management efficiency ratios could be used to measure how well Context Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.29 in 2025. Return On Capital Employed is likely to drop to -0.33 in 2025. At this time, Context Therapeutics' Total Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 58.3 M in 2025, whereas Other Assets are likely to drop 0.86 in 2025.Similar Executives
| Showing other executives | INSIDER Age | ||
| Eugene III | Biofrontera | 40 | |
| William MBA | Tscan Therapeutics | 54 | |
| Tomasz Kula | Tscan Therapeutics | N/A | |
| Geoffrey Birkett | Ensysce Biosciences | 62 | |
| Jaa Roberson | Day One Biopharmaceuticals | N/A | |
| Karen Bergman | Bolt Biotherapeutics | N/A | |
| Hermann Lubbert | Biofrontera | 68 | |
| Dr Roberts | Lyra Therapeutics | 56 | |
| Ming Yin | Bolt Biotherapeutics | N/A | |
| MSE MBA | Ensysce Biosciences | 52 | |
| PharmD Chiodin | Day One Biopharmaceuticals | N/A | |
| Randall Schatzman | Bolt Biotherapeutics | 69 | |
| Julie MBA | Day One Biopharmaceuticals | 42 | |
| Gavin MacBeath | Tscan Therapeutics | 55 | |
| Erica CPA | Biofrontera | 39 | |
| Ray Lockard | Tscan Therapeutics | N/A | |
| Edith MD | Bolt Biotherapeutics | 67 | |
| Bruce MD | Bolt Biotherapeutics | N/A | |
| Donald MBA | Lyra Therapeutics | 70 | |
| Jeffrey Millard | Ensysce Biosciences | 49 | |
| Edgar MD | Bolt Biotherapeutics | 78 | |
Management Performance
| Return On Equity | -0.37 | ||||
| Return On Asset | -0.25 |
Context Therapeutics Leadership Team
Elected by the shareholders, the Context Therapeutics' board of directors comprises two types of representatives: Context Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Context. The board's role is to monitor Context Therapeutics' management team and ensure that shareholders' interests are well served. Context Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Context Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jennifer MBA, Senior Operations | ||
| Martin Lehr, President, CoFounder | ||
| Christopher MBA, Senior Operations | ||
| Tarek MD, Chief Officer | ||
| Jennifer MinaiAzary, CFO Treasurer | ||
| JD Esq, Chief Secretary | ||
| Claudio MD, Chief Officer | ||
| Karen MD, Chief Officer | ||
| Felix Kim, Cofounder Board | ||
| LLM MBA, Interim Director | ||
| Alex Esq, Chief Secretary | ||
| Elizabeth CPA, Controller | ||
| Jeffrey Liebman, Associate Accounting | ||
| Evan Dick, VP RD |
Context Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Context Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.37 | ||||
| Return On Asset | -0.25 | ||||
| Current Valuation | (2.34 M) | ||||
| Shares Outstanding | 89.7 M | ||||
| Shares Owned By Insiders | 2.32 % | ||||
| Shares Owned By Institutions | 76.78 % | ||||
| Number Of Shares Shorted | 506.95 K | ||||
| Price To Book | 0.98 X | ||||
| EBITDA | (26.67 M) | ||||
| Net Income | (26.73 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Context Stock Analysis
When running Context Therapeutics' price analysis, check to measure Context Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Context Therapeutics is operating at the current time. Most of Context Therapeutics' value examination focuses on studying past and present price action to predict the probability of Context Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Context Therapeutics' price. Additionally, you may evaluate how the addition of Context Therapeutics to your portfolios can decrease your overall portfolio volatility.